share_log

SD: Specialized disclosure report

SEC announcement ·  May 17 23:33
Summary by Futu AI
Novo Nordisk A/S, a leading healthcare company, has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission. The report, which covers the period from January 1 to December 31, 2023, details the company's compliance with Rule 13p-1 under the Securities Exchange Act concerning conflict minerals. The Conflict Minerals Report, which is a key component of the filing, is available for public access on Novo Nordisk's website. This annual disclosure is part of the company's commitment to sustainable business practices and governance. The report was signed by Executive Vice President & Chief Financial Officer, Karsten Munk Knudsen, on May 17, 2024.
Novo Nordisk A/S, a leading healthcare company, has filed its Specialized Disclosure Report (Form SD) with the United States Securities and Exchange Commission. The report, which covers the period from January 1 to December 31, 2023, details the company's compliance with Rule 13p-1 under the Securities Exchange Act concerning conflict minerals. The Conflict Minerals Report, which is a key component of the filing, is available for public access on Novo Nordisk's website. This annual disclosure is part of the company's commitment to sustainable business practices and governance. The report was signed by Executive Vice President & Chief Financial Officer, Karsten Munk Knudsen, on May 17, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.